Viatris, Inc. VTRS 深 沪
已收盘 03-27 16:00:00 美东时间
13.05
-0.320
-2.39%
华盛通- 最 高13.39
- 今 开13.36
- 成交量 499.52万股
- 最 低 13.03
- 昨 收 13.37
- 总市值 150.26亿
- 52周最高 16.35
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 6.37
- 委 比 21.46%
- 总股本 11.51亿
- 历史最高 16.49
- 量 比 0.48
- 振 幅 2.69%
- 历史最低 6.37
- 每 手 1
- 风险率 2.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insider trades: CrowdStrike, Palo Alto, Lululemon among notable names
Insider trades were seen across companies like Palo Alto Networks (PANW), Dell (DELL) and Taiwan Semiconductor (TSM) this week. The following transactions occurred between March 23 to March 27. CrowdS...
03-28 23:03
TeraWulf, Viatris, MGM, Nucor, Best Buy Shake-Up
Insiders have been trading these 5 stocks: (($WULF)), (($VTRS)), (($MGM)), (($N...
03-28 21:01
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Barclays Maintains Overweight on Viatris, Raises Price Target to $17
Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $15 to $17.
03-24 22:10
BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Cencora, Stryker
BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Cencora, Stryker Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 20 (Reuters) - The main U.S. indexes were on track to open highe
03-23 21:08
BUZZ-Viatris rises after Japan approves anxiety disorder drug
BUZZ-Viatris rises after Japan approves anxiety disorder drug ** Shares of drugmaker Viatris VTRS.O rise 2% to $13.47 premarket ** Co says Japan approved its drug Effexor to treat generalized anxiety disorder ** Approval makes Effexor the first medicine cleared for the condition in Japan, co says **
03-23 20:14
Citi's top large-cap stocks with positive ROE trends
Citi has updated its return-on-equity trend baskets. "We created the ROE Trend Baskets which focus on forward ROE improvement driven by improving margins and higher total asset turnover, not financial...
03-22 21:54
Theravance Biopharma Q4 net income hits USD 61.02 million as total revenue rises 145% to USD 45.89 million
Theravance Biopharma Q4 net income hits USD 61.02 million as total revenue rises 145% to USD 45.89 million Theravance published a press release reporting Q4 and full-year 2025 results, including Q4 total revenue of USD 45.89 million and Q4 net income of USD 61.02 million. Viatris collaboration reven
03-19 20:32
Viatris forecasts 9%-10% adjusted EPS CAGR through 2030 and more than USD 3 billion free cash flow in 2030
Viatris forecasts 9%-10% adjusted EPS CAGR through 2030 and more than USD 3 billion free cash flow in 2030 Viatris set combined long-term targets through 2030 of 5% to 6% total revenues CAGR and 7% to 8% adjusted EBITDA CAGR. Adjusted EPS is expected to grow at a 9% to 10% CAGR, with annual free cas
03-19 20:31
GoodRx Partners With Viatris To Offer Major Brand Medications At A Discount
Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc®GoodRx (NASDAQ:GDRX), the leading platform for
03-11 21:05
